{"schema_version":"secwatch.filing_event.v1","accession":"0001635088-26-000060","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2026-05-20T11:14:10+00:00","discovered_at":"2026-05-20T11:15:00.234160+00:00","generated_at":"2026-05-20T11:15:28.044653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant reports Q4 GAAP EPS $0.28 on Moderna settlement; IMVT-1402 D2T RA ACR20 72.7%","bullets":["Q4 GAAP income from continuing ops $355.7M ($0.28 diluted EPS) vs loss of $252.4M ($0.29 loss) YoY; includes $770M gain on Moderna settlement.","Non-GAAP loss from continuing ops $222.7M in Q4 vs $154.4M loss YoY; FY loss $747.7M vs $623.9M.","IMVT-1402 in D2T RA: Week 16 ACR20 72.7%, ACR50 54.5%, ACR70 35.8% in open-label period; 170 patients enrolled.","Brepocitinib NDA for DM accepted with Priority Review; launch by end Sep 2026. Breakthrough Therapy for cutaneous sarcoidosis.","Moderna settlement: $2.25B global; $950M due July 2026; additional $1.3B contingent on appeal resolution."],"urls":{"canonical":"https://secwatch.observer/filing/0001635088-26-000060","json":"https://secwatch.observer/filing/0001635088-26-000060.json","markdown":"https://secwatch.observer/filing/0001635088-26-000060.md","text":"https://secwatch.observer/filing/0001635088-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/roiv-20260520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T11:15:28.044653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45519c433c69e815f019eb6ceb6628b043ebf514","claim":"Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2026.","evidence_excerpt":"On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}